8-K: Oramed Pharmaceuticals Announces $75 Million At-the-Market Offering and Termination of Previous Agreement

Oramed Pharmaceuticals has entered into a new at-the-market offering agreement for up to $75 million in common stock and terminated a prior agreement with Cantor Fitzgerald.

Summary

• Oramed Pharmaceuticals has entered into an at-the-market (ATM) offering agreement with Rodman & Renshaw LLC and StockBlock Securities LLC to sell up to $75 million of its common stock.
• The company will pay the agents a commission of up to 3.0% of the gross proceeds from the sale of shares.
• Oramed also terminated its previous controlled equity offering agreement with Cantor Fitzgerald, which had allowed for the sale of up to $100 million in stock.
• Prior to termination, Oramed received approximately $26.25 million in net proceeds from the Cantor Fitzgerald agreement.
• The new ATM agreement allows the agents to sell shares through various methods, including directly on the Nasdaq Capital Market or in privately negotiated transactions.
• The company is not obligated to sell any shares under the new agreement, and the agents are not obligated to buy or sell any shares.
• The ATM agreement can be terminated by any party with five days' notice.

Sentiment

Score: 6

Explanation: The document is neutral to slightly positive. While it announces a potential capital raise, it also highlights the flexibility and strategic shift in Oramed's approach. The lack of obligation to sell shares and the termination clause introduce some uncertainty.

Positives

• The new ATM agreement provides Oramed with a flexible mechanism to raise capital.
• The company has access to a potential $75 million in funding.
• The termination of the Cantor Fitzgerald agreement did not incur any penalties.
• The company has multiple options for selling shares, including direct sales on the Nasdaq.

Negatives

• The company is not obligated to sell any shares, and the agents are not obligated to buy or sell any shares, so there is no guarantee of capital being raised.
• The company will incur commissions of up to 3.0% on any shares sold.
• The ATM agreement can be terminated by any party with five days' notice, creating uncertainty.

Risks

• There is no guarantee that Oramed will be able to sell any shares under the new ATM agreement.
• The price and amount of shares sold are uncertain.
• The company is subject to market conditions and investor demand.
• The agreement can be terminated by any party with five days' notice, creating uncertainty.

Future Outlook

Oramed has the option to sell up to $75 million in common stock through the new ATM agreement, but there is no guarantee of the amount or timing of any sales. The company will use the net proceeds as described in the prospectus.

Management Comments

• The document includes a signature from Nadav Kidron, President and CEO of Oramed Pharmaceuticals Inc.

Industry Context

At-the-market offerings are a common method for publicly traded companies, particularly in the biotech and pharmaceutical sectors, to raise capital. This allows companies to take advantage of market conditions and investor demand without the need for a traditional underwritten offering. The termination of the previous agreement and entry into a new one suggests a strategic shift in Oramed's capital raising approach.

Comparison to Industry Standards

• At-the-market offerings are a common practice for companies like Oramed, especially in the biotech sector, to raise capital opportunistically.
• The commission rate of up to 3.0% is within the typical range for ATM offerings.
• The $75 million offering size is moderate compared to some larger biotech companies, but appropriate for Oramed's current market capitalization and funding needs.
• Comparable companies that have used ATM offerings include companies such as Cassava Sciences, Inc. and Amylyx Pharmaceuticals, Inc.

Stakeholder Impact

• Shareholders may experience dilution if Oramed sells a significant number of shares.
• The company's ability to fund its operations and research may be improved.
• The company's financial position may be strengthened.

Next Steps

• Oramed may begin selling shares under the new ATM agreement.
• The company will need to monitor market conditions and investor demand.
• The company will need to file required reports with the SEC and Nasdaq.

Key Dates

Keywords

at-the-market offering, common stock, capital raise, Rodman & Renshaw, StockBlock Securities, Cantor Fitzgerald, equity offering, Nasdaq, securities, pharmaceuticals